nference Partners with Parabilis Medicines for AI Research in Colorectal Cancer

CAMBRIDGE, Mass.--In a significant development, nference has announced a strategic research and data science partnership with Parabilis Medicines, Inc. This collaboration aims to support the clinical development of Parabilis' lead program, FOG-001, which targets colorectal cancer. Through this partnership, Parabilis' researchers will gain access to an extensive repository of clinical data from millions of cancer patients, sourced from leading medical institutions.

The partnership will leverage nference's advanced machine learning models to power the nSights platform, which will provide contextual insights for Parabilis' single-arm clinical trial data. This platform is designed to aid in identifying clinical biomarkers and understanding target identification. Furthermore, it will facilitate the accurate characterization of real-world outcomes in patient groups that could benefit from Parabilis' FOG-001, a beta-catenin inhibitor currently under investigation in a Phase 1/2 clinical trial for colorectal cancer. This type of cancer remains one of the most common and challenging to treat globally.

Dr. AJ Venkatakrishnan, SVP of Strategic AI Partnerships at nference, emphasized the company's dedication to advancing cancer care through the use of AI and real-world patient data to uncover valuable insights that drive better treatment outcomes. He stated, "At nference, we are committed to advancing cancer care by harnessing AI and real-world patient journeys to unlock valuable insights that can drive better treatment outcomes."

Aaron Mathias, VP of Business Development & Corporate Strategy at nference, highlighted the potential of their biomedical research capabilities to accelerate Parabilis' innovative work in developing Helicon™ therapeutics. He remarked, "By leveraging our nSights platform and biomedical research capabilities, we aim to accelerate Parabilis' groundbreaking work in developing Helicon™ therapeutics, offering new hope for patients with difficult-to-treat cancers."

Dr. Brandon Allgood, Chief Data Science Officer at Parabilis, expressed enthusiasm about the collaboration, noting that the nSights platform will enable Parabilis to access a vast amount of real-world, multimodal clinical data. This access will be instrumental in identifying optimal patient populations and improving targeting strategies for their programs. He said, "The nSights platform will enable us to tap into a large depth of real-world, multimodal clinical data, helping us identify optimal patient populations and improve the targeting of our programs. By combining advanced AI, robust computational methods, and a continuous learning system built on our growing data repository, we are creating a transformative platform that not only accelerates drug discovery and development but also increases the precision and success of our therapeutic programs."

nference is at the forefront of unlocking the potential of healthcare data with AI, providing real-world evidence, insights, and solutions informed by comprehensive multimodal data spanning all therapeutic areas. Their extensive de-identified, longitudinal data includes clinical notes, patient histories, vitals, lab tests, radiology images, digital pathology, genomics, and electrophysiology waveforms. Their federated data platform, comprised of premier healthcare organizations such as Mayo Clinic, Duke Health, Banner Health, Vanderbilt University Medical Center, and Emory Healthcare, enhances advanced research and custom AI model development. This invaluable access to data from over 40 million patient journeys allows partners to accelerate target discovery, optimize clinical trial design, and improve lifecycle management.

Parabilis Medicines is a clinical-stage biopharmaceutical company focused on developing innovative medicines for cancer patients. Utilizing their Helicon™ discovery platform, Parabilis is engineering stabilized helical peptide therapeutics to address traditionally undruggable targets. Their lead clinical program, FOG-001, is undergoing a Phase 1/2 study for colorectal cancer and other solid tumors. The company is also advancing other first-in-class programs targeting proteins relevant to various cancers but considered challenging to address with conventional drug modalities. Parabilis' versatile Helicon approach allows for the discovery of multiple targeting mechanisms, including protein-protein interaction inhibitors, bifunctional degraders, and radioligand therapeutics. The company is headquartered in Cambridge, Mass., and has secured over $500 million in funding from leading life sciences investors.